Original article
There are countless attempts to improve or reform the healthcare system every day. The problem is always the same: There is a historically developed and seemingly complex system that is exposed to numerous different interests and only allows changes slowly. There are only a few thought leaders who continue to advance the system with a free spirit and creativity. Furthermore, it is often dismissed as utopia to completely reinvent it. The concept presented here for the design of a new healthcare system can be derived from the approach of the fashion and automotive industries.
28.05.2013
There are countless attempts to improve or reform the healthcare system every day. The problem is always the same: There is a historically developed and seemingly complex system that is exposed to numerous different interests and only allows changes slowly. There are only a few thought leaders who continue to advance the system with a free spirit and creativity. Furthermore, it is often dismissed as utopia to completely reinvent it. The concept presented here for the design of a new healthcare system can be derived from the approach of the fashion and automotive industries.
28.05.2013
Der Verein für Psychiatrie und seelische Gesundheit (VPsG) wurde im Dezember 2003 auf Initiative vor allem niedergelassener Nervenärzte, Psychiater und Psychotherapeuten gegründet und arbeitet – was selten ist in Deutschland – sektorübergreifend und multiprofessionell. MVF sprach mit Dr. Norbert Mönter, dem ersten Vorsitzenden des VPsG, der heute – zehn Jahre nach seiner Gründung – 230 persönliche (niedergelassene Nervenärzte/Psychiater, Kliniker, Psychotherapeuten, Soziotherapeuten, Ergotherapeuten u.a.) bzw. korporative Mitglieder (Kliniken, psychosoziale Träger und Fachpflegedienste) zählt. Vertragspartner der Krankenkassen für Verträge zur Integrierten Versorgung ist die anagementgesellschaft des Vereins, die PIBB – Psychiatrie Initiative Berlin Brandenburg.
28.05.2013
What about the “rare” ones in Germany? To clarify this question, the company Genzyme invited people to a press conference on the occasion of Rare Disease Day. Among others, two physicians reported at the event on their clinical practice in the diagnosis and treatment of orphan diseases. Both in detail - using the example of the diagnosis of Pompe disease - and in general - with regard to the treatment of rare metabolic disorders - the lectures showed that the care for patients with rare diseases in Germany is not sufficient. The error lies in the system – and in the lack of networking between the players.
28.05.2013
In der Podiumsdiskussion „Wege aus dem Innovationsstau“ wurde unter Moderation von Prof. Dr. Dr. Alfred Holzgreve (Vivantes) die erste Vortragssession resümiert. Es dikutierten die Vortragenden Dr. Stefan Etgeton (Bertelsmann Stiftung), Prof. Dr. Bertram Häussler (IGES Institut), Prof. Dr. Wolfgang Greiner (Universität Bielefeld), Prof. Dr. Neugebauer (IFOM, Köln), es meldeten sich zu Wort Helmut Hildebrandt (OptiMedis) und Antje Domscheit (BVA).
28.05.2013
To promote innovative cross-sectoral forms of care and for health care research, an innovation fund financed by the health insurance companies is to be created, 75 percent of which will flow into research into the content of standard care and a quarter into health care research. That's at least 75 million euros for health services research alone, far less than the German Network for Health Services Research and the Health Advisory Council have been calling for around 300 million euros for many years, but still. Josef Hecken, the impartial chairman of the Federal Joint Committee, has already announced that the first money from this fund should flow in the second half of 2014. The question will be: where does this money go? And: What exactly should be researched? Will it be outcome-driven research that works top down from the most important to the less important topics. Incidentally, such a maxim for action was included in the key points paper of a “National Action Plan for Health Services Research”, which was presented jointly by the German Network for Health Care Research and the Bertelsmann Foundation in the Bertelsmann representative office at Unter den Linden 1, the former commandant's house in Berlin, the very room in which the 4th The specialist congress of “Monitor Healthcare Research” took place under the title “Innovation 2014” and in cooperation with the Bertelsmann company arvato healthcare and the BKK umbrella organization.
28.05.2013
If you enter the keyword “integrated care” into Google, you get 470,000 hits – the term “standard care” leads to 443,000 results. This numerical ratio reflects well the health policy discussions of the last few years. However, it is far from a reflection of the supply landscape. 14 years after the introduction of IV, it still has a niche existence in the German health system. In recent years, only 0.7 to 0.8 percent of health spending has flowed into integrated care. In addition, the number of IV contracts has been stagnating for years. This leaves considerable untapped potential for a better and more efficient healthcare system.
28.05.2013
As the US health economist Prof. Dr. Uwe E. Reinhardt, Princeton University, who last spoke at an annual congress of the Federal Managed Care Association, criticized above all that the health policy debate in Germany is always about income distribution, not about patients. That was in September 2000. In January 2014 he was back again, calling Obamacare a “disgusting Band-Aid for a disgusting system” at the BMC convention. “Monitor Healthcare Research” spoke to the controversial economist, who didn’t mince his words: “The president and his people have failed as project managers.”
28.05.2013
When it comes to medication provision, there are clear differences between private and statutory health insurance. The latest figures are provided by the current study by the Scientific Institute of PKV (WIP) on “Medicine supply for privately insured people 2012”. The analysis shows clear differences in drug prescribing practices, which demonstrate greater freedom of choice and therapy as well as innovation-friendliness in private health insurance. The WIP drug study provides a comprehensive analysis of the PKV drug market. It closes a gap in the drug prescription report, which can only reflect the events of the statutory health insurance.
28.05.2013
Few topics currently occupy Berlin's health policy circles as intensely as the innovation fund announced in the coalition agreement. Claims are being made or denied, and numerous models for the process of distributing the funds are being developed. Many questions remain open and are being hotly debated.